1 Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of Missouri, Columbia, Missouri, USA.
2 Division of Surgical Oncology, Baptist MD Anderson Cancer Center, Jacksonville, Florida, USA.
Otolaryngol Head Neck Surg. 2019 Feb;160(2):261-266. doi: 10.1177/0194599818794479. Epub 2018 Aug 21.
To understand the effects of positron emission tomography/computed tomography (PET/CT) evaluation on patients with previously untreated head and neck squamous cell carcinoma (HNSCC) with clinical evidence of regional lymph node involvement.
Prospective blinded study.
Tertiary care cancer center.
Informed consent was obtained and data collected from 52 consecutive previously untreated patients with HNSCC and clinical evidence of cervical metastasis. All patients underwent conventional evaluation for HNSCC and whole body PET/CT. Data were evaluated by 5 independent reviewers, who performed TNM staging per the American Joint Committee on Cancer (seventh edition) manual and proposed a treatment plan prior to viewing, and after reviewing, PET/CT. Cases where at least 3 of 5 reviewers agreed were considered significant.
There were 0 patients for whom review of the PET/CT altered the T-class assessment (95% CI, 0-6.8), 12 (23.1%) for whom PET/CT altered N classification (95% CI, 12.5-34.5), and 2 (3.8%) for whom PET/CT altered the M classification (95% CI, 0.5-13.2). For 5 patients (9.6%), overall stage was altered per PET/CT review (95% CI, 3.2-21). For 3 patients (5.8%), PET/CT findings prompted reviewers to alter treatment recommendations (95% CI, 1.2-15.9).
When added to more conventional patient evaluation, PET/CT results in changes to the TNM categories, but overall staging and treatment were less frequently affected. Whether PET/CT should be used routinely for patients with stage III and IV HNSCC is still subjective and merits further study.
了解正电子发射断层扫描/计算机断层扫描(PET/CT)评估对有临床证据表明区域淋巴结受累的初治头颈部鳞状细胞癌(HNSCC)患者的影响。
前瞻性、盲法研究。
三级癌症中心。
获得 52 例初治 HNSCC 且有颈部转移临床证据的连续患者的知情同意并收集数据。所有患者均接受 HNSCC 常规评估和全身 PET/CT。5 位独立评审员对数据进行评估,根据美国癌症联合委员会(第七版)手册进行 TNM 分期,并在查看前和查看后对 PET/CT 提出治疗计划。至少有 5 位评审员中的 3 位同意的病例被认为具有重要意义。
有 0 例患者的 PET/CT 审查改变了 T 类评估(95%置信区间,0-6.8),12 例(23.1%)的患者 PET/CT 改变了 N 分类(95%置信区间,12.5-34.5),2 例(3.8%)的患者 PET/CT 改变了 M 分类(95%置信区间,0.5-13.2)。根据 PET/CT 审查,5 例(9.6%)患者的总体分期发生改变(95%置信区间,3.2-21)。3 例(5.8%)患者的 PET/CT 结果促使评审员改变了治疗建议(95%置信区间,1.2-15.9)。
当将 PET/CT 添加到更常规的患者评估中时,结果会改变 TNM 类别,但总体分期和治疗受影响的频率较低。对于 III 期和 IV 期 HNSCC 患者是否应常规使用 PET/CT 仍存在主观性,值得进一步研究。